Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00730145 · ClinicalTrials.gov registry record · Phase 1
A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT00730145 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 8 participants.
The verdict
NCT00730145, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
1. Quantify how much PD-0332334 is removed from the blood with hemodialysis 2. Investigate the pharmacokinetics of a single dose of PD-0332334 in subjects receiving regular hemodialysis treatments. 3. Investigate the safety and tolerability of a single dose of PD-0332334 in subjects receiving hemodialysis.
Interventions
- DRUG PD-0332334
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2008-09 |
| Est. Completion | 2009-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00730145
The ClinicalTrials.gov registry entry for NCT00730145 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PD-0332334 is the first listed.
NCT00730145 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00730145 about?
NCT00730145 is a clinical study titled "A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis". 1. Quantify how much PD-0332334 is removed from the blood with hemodialysis 2. Investigate the pharmacokinetics of a single dose of PD-0332334 in subjects receiving regular hemodialysis treatments. 3. Investigate the safety and tolerability of a single dose of PD-0332334 in subjects receiving hemodi...
What is the current status of trial NCT00730145?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2008-09. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00730145?
The interventions under investigation include: PD-0332334 (DRUG).
Who is sponsoring clinical trial NCT00730145?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.